Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unresectable Colorectal Cancer (DIAMOND Study): A Randomized Phase III of PRODIGE Intergroup

NCT06446557 is registered in ClinicalTrials.gov with University Hospital, Rouen as lead sponsor.

NCT NCT06446557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06446557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unresectable Colorectal Cancer (DIAMOND Study): A Randomized Phase III of PRODIGE Intergroup
Lead sponsor
University Hospital, Rouen
Phase
Phase 3
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
June 1, 2032
Enrollment
408 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colon cancer